Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates--the VIVA II study.
The effectiveness of bisphosphonate treatment for post-menopausal osteoporosis depends on patients adhering to the therapeutic regimen. We previously showed that patients prefer a once-monthly regimen and the present follow-up study aimed to analyse patients' motivation for this preference. Women with post-menopausal osteoporosis (n = 2035) completed a questionnaire targeting their bisphosphonate treatment preferences. The majority had chosen the once-monthly regimen due to the comfort (69%) and simplicity (59%) of the treatment and the need to take fewer pills (55%). Friends, relatives and print media were highlighted as important sources of information and many patients indicated a need for more information about osteoporosis and its management. Gastrointestinal and muscular side-effects were reported by about one-third of the patients, but these were well tolerated. It is concluded that once-monthly bisphosphonate treatment was preferred due to improved quality of life and should be offered to all patients with post-menopausal osteoporosis.
Payer
J
J
Fifth Department of Internal Medicine, Faculty Hospital, Comenius University, Bratislava, Slovakia.
Cierny
D
D
Killinger
Z
Z
Sulková
I
I
Behuliak
M
M
Celec
P
P
D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D054626:Consumer Health Information; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D033181:Information Dissemination; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D017060:Patient Satisfaction; D011788:Quality of Life; D011795:Surveys and Questionnaires
D050071:Bone Density Conservation Agents; D004164:Diphosphonates